Figure 4.

In vitro 3D models to test the efficacy of immunotherapeutics in a personalized approach strategy. On the left, the functional assay for cancer responsiveness to checkpoint inhibitors using VITVO bioreactor described by Candini et al. (88); on the right, TCR T-cell activity against tumor using 3D microfluidic device described by Pavesi and colleagues (83).